Cumulative evidence indicates that the modulating self-renewal pathways of CSCs are a promising strategy for cancer therapy [52,53,54] since these self-renewing and extremely tumorigenic CD133-overexpressing subpopulations have been clinically observed to produce poor clinical outcomes [55]. This evidence concerns the gene PROM1 and cancer.